Trump signs order to expedite psychedelic drug research amid Iran tensions

President Trump has signed an executive order to speed up access to psychedelic drug research and treatment. Separately, U.S.-Iran tensions continue to weigh on Polymarket contracts. Trump’s agreement to Iranian demands in April sits at 36.5% YES, down from 62% yesterday.

## Market reaction

The 14.5-point drop reflects increased skepticism about Trump conceding to Iranian demands as potential Iranian retaliation in the Strait of Hormuz raises the cost of diplomatic concessions. April 22 peace deal odds also fell to 16.5% YES, with traders pricing in low chances of a diplomatic breakthrough in the next four days.

## Why it matters

The April 30 contract at 33.5% YES suggests traders expect possible mid-April catalysts but remain cautious. The order book depth is $818 to move odds by 5 points, so thin liquidity means small trades can swing prices significantly.

The psychedelics executive order and the Iran contracts are unrelated policy areas, but both are active simultaneously. On the Iran side, traders are pricing in skepticism about a rapid resolution, consistent with the historical pattern that unilateral U.S. actions rarely produce quick diplomatic outcomes.

## What to watch

Watch for CENTCOM announcements or shifts in Iranian military posturing in the Strait of Hormuz. A change in operational language from either side could move these contracts sharply.

## API access

Get prediction market intelligence as a structured API feed. Early access waitlist.